Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)
Bullboard Posts
User Avatar Image
(61)
•••
Comment by Canadian_101on Jun 01, 2020 10:40am
259 Views
Post# 31096121

RE:RE:Pump And Dump

RE:RE:Pump And Dump
If you listen to what Robert said he stated  phase 2 results should be good and released by end of June,  once released a phase 3 trial will be needed which is pretty much standard procedure in drug trials. My guess is he still holds all his shares and will continue to hold untill this drugs gets to the market.

Glad I bought in at 42 censt and will buy more today ont he drop, the results were great!!!!!!


https://www.bnnbloomberg.ca/market-call/robert-mcwhirter-discusses-antibe-therapeutics~1968070

i





Pandora wrote:
Duster340 wrote: on friday by mcwhirter, do you guys feel that you have been played, i am sure his family was dumping those 200k share at the peak spike on friday. what do you guys think?


Talk about sell on news! That news was not well received. Pushing 15M shares traded already and down 13 cents. Whoa!



Bullboard Posts
Dealroom for high-potential pre-IPO opportunities